C4 Therapeutics (CCCC) Return on Capital Employed (2020 - 2026)
C4 Therapeutics' quarterly Return on Capital Employed came in at 35.94% in Q1 2026, up 374.0% year-on-year from 7.58% in Q1 2025, and up 12.89% quarter-over-quarter from 41.26% in Q4 2025.
C4 Therapeutics has reported Return on Capital Employed for 7 years, with the latest figure at 35.94% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed rose 374.0% year-over-year to 35.94%; the trailing twelve-month figure through Mar 2026 stood at 35.94% (up 374.0% YoY), and the FY2025 full-year result was 35.86%, up 177.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 35.94%, up from 41.26% in the prior quarter.
- The five-year high for Return on Capital Employed was 20.04% in Q1 2022, with the low at 52.96% in Q3 2025.
- Average Return on Capital Employed over 5 years is 37.12%, with a median of 37.66% recorded in 2024.
- Year-over-year, Return on Capital Employed slumped 2140 bps in 2023 and surged 762 bps in 2024.
- Tracing CCCC's Return on Capital Employed over 5 years: stood at 32.26% in 2022, then plunged by 38 bps to 44.57% in 2023, then gained by 16 bps to 37.66% in 2024, then fell by 10 bps to 41.26% in 2025, then advanced by 13 bps to 35.94% in 2026.
- The last three Return on Capital Employed figures came in at 35.94% (Q1 2026), 41.26% (Q4 2025), and 52.96% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 20.34% |
| 10 | C4 Therapeutics | 561.03 Mn | 325.36 Mn | - | -35.94% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -35.94% |
| Dec 31, 2025 | -41.26% |
| Sep 30, 2025 | -52.96% |
| Jun 30, 2025 | -46.90% |
| Mar 31, 2025 | -39.68% |
| Dec 31, 2024 | -37.66% |
| Sep 30, 2024 | -35.59% |
| Jun 30, 2024 | -35.44% |
| Mar 31, 2024 | -40.62% |
| Dec 31, 2023 | -44.57% |
| Sep 30, 2023 | -43.21% |
| Jun 30, 2023 | -42.87% |
| Mar 31, 2023 | -35.93% |
| Dec 31, 2022 | -32.26% |
| Sep 30, 2022 | -24.67% |
| Jun 30, 2022 | -21.46% |
| Mar 31, 2022 | -20.04% |
| Dec 31, 2021 | -18.01% |
| Sep 30, 2021 | -18.27% |
| Jun 30, 2021 | -19.62% |
| Mar 31, 2021 | -19.64% |
| Dec 31, 2020 | -22.32% |